Development of a TCR beta repertoire assay for profiling liquid biopsies from NSCLC donors

Abstract

Aim: The aim of this study was to demonstrate the utility of T-Cell receptor beta (TCRβ) sequencing as a robust method for assessing T-cell repertoire changes in donors with non-small cell lung cancer (NSCLC). We further demonstrated the use of the assay by monitoring repertoire modulation in a defined model antigen system, cytomegalovirus (CMV).

Methods: Peripheral blood mononuclear cells from four healthy donors were challenged with a 1-week exposure to whole-cell lysate from CMV-infected cells or CMVpp65_495-503 peptide (NLVPMVATV). T-cell repertoire perturbations were assessed using the Oncomine TCR Beta-SR Assay and Ion GeneStudio S5 Plus Sequencer. A pp65 tetramer flow cytometry assay was used as an orthogonal method to assess clonal expansion of a subset of CMV-specific T-cells. For evaluation of the assay in peripheral blood lymphocytes from NSCLC donors, five whole blood specimens were evaluated using the same sequencing workflow.

Results: The TCR beta assay identified 6,683-61,936 unique clones from 1-2 million reads per sample, and an average of 80% of the total reads were usable for TCR profiling. In the NSCLC donors, TCR convergence and clonality values were consistent with published results and ranged 0.016-0.033 for convergence and 0.09-0.48 for clonality. In the CMV study, TCR sequencing detected the expansion of a common family of clones in all 4 samples in response to antigen stimulation. This expansion corresponded to an increase in pp65 tetramer staining by flow cytometry. Baseline TCR convergence scores ranged 0.009-0.041 and increased 5-fold in one sample as a result of pp65 antigen stimulation.

Conclusion: The results of this study demonstrated the utility of profiling of the TCRβ repertoire in a model system and in donors with NSCLC. Additionally, we demonstrated the correlation between RNA-seq methods and protein-tetramer analysis using flow cytometry. These techniques represent an emerging solution that could complement other liquid and tissue diagnostic assays in the clinic and will be of value in predicting host response/resistance and adverse events to immunotherapies. Prospective clinical studies are on-going in which the developed TCR beta assay will undergo further validation.

Keywords

TCRβ / liquid biopsy / Ion Torrent / immunotherapy

References

[1] Kirsch I,Robins H.T-cell receptor profiling in cancer..Mol Oncol2015;9:2063-70 PMCID:PMC5528728

[2] Page DB,Redmond D,Durack JC.Deep sequencing of T-cell receptor DNA as a biomarker of clonally expanded TILs in breast cancer after immunotherapy..Cancer Immunol Res2016;4:835-44 PMCID:PMC5064839

[3] Looney TJ,Lowman G,Hajjar J.Haplotype analysis of the T-cell receptor beta (TCRB) locus by long-amplicon TCRB repertoire sequencing..JIPO2019;2:137-143

[4] Looney TJ,Lowman G,Morrison C.TCR convergence in individuals treated with immune checkpoint inhibition for cancer..Front Immunol2020;10:2985 PMCID:PMC6962348

[5] Mellert H,Jackson L,Thurston S.Development and clinical utility of a blood-based test service for the rapid identification of actionable mutations in non-small cell lung carcinoma..J Mol Diagn2017;19:404-16

[6] ThermoFisher ScientificOncomine TCR Beta Assay: User Guide. Revision A.0 Pleasanton,2018;CAAuthor

[7] Medina Diaz I,Mehnert DH,Diehl F.Performance of streck cfDNA blood collection tubes for liquid biopsy testing..PLoS One2016;11:e0166354 PMCID:PMC5104415

[8] Pestano G, Jensen-Long L. Developing liquid biopsy diagnostic testing for cancer immunotherapy selection in NSCLC patients. MLO. Mar 22nd, 2018. Available from https://www.mlo-online.com/molecular/dna-rna/article/13009462/developing-liquid-biopsy-diagnostic-testing-for-cancer-immunotherapy-selection-in-nsclc-patients [Last accessed on 9 Jun 2020]